Blog
RSS FeedPosted by Michael Wonder on 04 Dec 2017
Brand name drug sales soar in Canada, while R&D sags
1 December 2017 - Patented drug industry disputes it's failing to invest enough into research and development. ...
Posted by Michael Wonder on 04 Dec 2017
Prescription drug costs should be fair – not cheap
4 December 2017 - "Canadians are not getting the value for money on prescription medicine spending or the outcomes they ...
Posted by Michael Wonder on 03 Dec 2017
Ottawa unveils new draft regulations for drug-pricing
2 December 2017 - The Trudeau government is plowing ahead with an overhaul of the country's drug-pricing rules, unveiling draft ...
Posted by Michael Wonder on 27 Nov 2017
Revised process for filing CDR submissions and resubmissions
27 November 2017 - The CADTH Common Drug Review is aligning the process for secure file sharing with the pan-Canadian ...
Posted by Michael Wonder on 23 Nov 2017
Canada-wide program aims to get young cancer patients faster access to new therapies
23 November 2017 - If Terry Fox were diagnosed today, he would fall among the 20 per cent of young ...
Posted by Michael Wonder on 16 Nov 2017
British Columbia and Prince Edward Island become the first provinces to add Erelzi (etanercept) to public drug plans for the treatment of multiple inflammatory diseases
16 November 2017 - Erelzi also becomes the first biosimilar indicated for polyarticular juvenile idiopathic arthritis under these provincial public drug ...
Posted by Michael Wonder on 15 Nov 2017
Revised procedure for the CADTH Common Drug Review resubmissions
13 November 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements ...
Posted by Michael Wonder on 31 Oct 2017
Drug firms warn Ottawa against ‘crippling’ price cuts
31 October 2017 - Canada's brand-name pharmaceutical companies are pushing back against a plan to overhaul Canada's drug-pricing regulator, saying ...
Posted by Michael Wonder on 23 Oct 2017
The serious flaw in Canada's health care system: prescription drugs aren't free
20 October 2017 - It’s often held up as an example to the world, but the Canadian system doesn’t cover essential ...
Posted by Michael Wonder on 11 Oct 2017
CDR Update — Issue 129
11 October 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission ...
Posted by Michael Wonder on 11 Oct 2017
Study finds significant overlap in the drugs covered by Canadian public drug plans
11 October 2017 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, ...
Posted by Michael Wonder on 02 Oct 2017
Revised procedure for advance notification of pending CDR submissions and resubmissions
28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...
Posted by Michael Wonder on 30 Sep 2017
Blacked-out information reveals secret world of drug prices
30 September 2017 - This week, the Patented Medicine Prices Review Board ruled the Canadian price of the drug Soliris is ...
Posted by Michael Wonder on 28 Sep 2017
Canadian regulator orders price cut of expensive U.S. drug Soliris
27 September 2017 - The maker of the one of the world's most expensive drugs has been ordered to slash ...
Posted by Michael Wonder on 12 Sep 2017
Australia proves national drug plan is possible for Canada
11 September 2017 - A Canadian doctor working in Australia has witnessed how its national drug plan, despite its flaws, is ...